-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF DECEMBER 3-9, 2023
December 2, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE Conference 12/05/2023 JAGX 27.4 9,151 $0.36 Conference 12/07/2023 BMEA 43.2 25,780 $16.68 FDA Event 12/08/2023 BCLI 52.0 5,135 $0.26 Conference 12/09/2023 APTO 32.4 76 $2.66 Conference 12/09/2023 INCY 27.1 38,201 $54.02 WEEK: 12/03/2023 – 12/09/2023
-
Jaguar Health | Presents December 5 at the MedInvest Oncology Investor Conference
Jaguar Health, a leading pharmaceutical company specializing in innovative treatments for various diseases, is set to present at the prestigious MedInvest Oncology Investor Conference on December 5. This highly anticipated event brings together top experts, investors, and industry leaders in the field of oncology. Jaguar Health’s participation at this conference is a testament to their…
-
Biomea Fusion | Presenting New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
NASDAQ: BMEA BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes STOCK & PRESS RELEASE INFO
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF OCTOBER 29 – NOVEMBER 4, 2023
October 28, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE Conference 11/02/2023 ARDX 22.5 27,193 $3.49 Conference 11/02/2023 ELDN 44.2 278 $1.59 Conference 11/03/2023 ACET 36.3 90 $1.26 Conference 11/03/2023 AUPH 23.5 11,055 $7.19 FDA Event 11/04/2023 CRBP 94.6 6,911 $5.21 WEEK: 10/29/2023 – 11/04/2023
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF OCTOBER 22-28, 2023
October 20, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE FDA Event 10/22/2023 REGN 3.0 600 $808.47 Conference 10/22/2023 RVMD 37.7 33,800 $27.97 Conference 10/23/2023 HARP 52.4 307 $6.88 FDA Event 10/26/2023 CPRX 13.9 2,074 $12.80 WEEK: 10/22/2023 – 10/28/2023
-
Aquestive Therapeutics | FDA Acceptance of Libervant™ for Treatment of Seizure Clusters in Young Patients
NASDAQ: AQST The FDA has recently accepted the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film, aiming to tackle the treatment of seizure clusters in children between the ages of two and five. This development provides hope for young patients and their families who have pbeen struggling with the challenges of managing seizure clusters.…